Human Gene MAPT (uc002ijr.4) Description and Page Index
  Description: Homo sapiens microtubule-associated protein tau (MAPT), transcript variant 1, mRNA.
RefSeq Summary (NM_016835): This gene encodes the microtubule-associated protein tau (MAPT) whose transcript undergoes complex, regulated alternative splicing, giving rise to several mRNA species. MAPT transcripts are differentially expressed in the nervous system, depending on stage of neuronal maturation and neuron type. MAPT gene mutations have been associated with several neurodegenerative disorders such as Alzheimer's disease, Pick's disease, frontotemporal dementia, cortico-basal degeneration and progressive supranuclear palsy. [provided by RefSeq, Jul 2008].
Transcript (Including UTRs)
   Position: hg19 chr17:43,971,748-44,105,699 Size: 133,952 Total Exon Count: 14 Strand: +
Coding Region
   Position: hg19 chr17:44,039,704-44,101,537 Size: 61,834 Coding Exon Count: 13 

Page IndexSequence and LinksUniProtKB CommentsGenetic AssociationsMalaCardsCTD
Gene AllelesRNA-Seq ExpressionMicroarray ExpressionRNA StructureProtein StructureOther Species
GO AnnotationsmRNA DescriptionsPathwaysOther NamesModel InformationMethods
Data last updated: 2013-06-14

-  Sequence and Links to Tools and Databases
 
Genomic Sequence (chr17:43,971,748-44,105,699)mRNA (may differ from genome)Protein (758 aa)
Gene SorterGenome BrowserOther Species FASTAVisiGeneGene interactionsTable Schema
BioGPSCGAPEnsemblEntrez GeneExonPrimerGeneCards
GeneNetworkHGNCHPRDLynxMGIneXtProt
OMIMPubMedReactomeStanford SOURCETreefamUniProtKB
Wikipedia

-  Comments and Description Text from UniProtKB
  ID: TAU_HUMAN
DESCRIPTION: RecName: Full=Microtubule-associated protein tau; AltName: Full=Neurofibrillary tangle protein; AltName: Full=Paired helical filament-tau; Short=PHF-tau;
FUNCTION: Promotes microtubule assembly and stability, and might be involved in the establishment and maintenance of neuronal polarity. The C-terminus binds axonal microtubules while the N- terminus binds neural plasma membrane components, suggesting that tau functions as a linker protein between both. Axonal polarity is predetermined by TAU/MAPT localization (in the neuronal cell) in the domain of the cell body defined by the centrosome. The short isoforms allow plasticity of the cytoskeleton whereas the longer isoforms may preferentially play a role in its stabilization.
SUBUNIT: Interacts with PSMC2 through SQSTM1 (By similarity). Interacts with SQSTM1 when polyubiquitinated. Interacts with FKBP4 (By similarity). Binds to CSNK1D. Interacts with SGK1.
INTERACTION: P05067:APP; NbExp=9; IntAct=EBI-366182, EBI-77613; Q9UNE7:STUB1; NbExp=2; IntAct=EBI-366182, EBI-357085;
SUBCELLULAR LOCATION: Cytoplasm, cytosol. Cell membrane; Peripheral membrane protein; Cytoplasmic side. Cytoplasm, cytoskeleton. Cell projection, axon. Note=Mostly found in the axons of neurons, in the cytosol and in association with plasma membrane components.
TISSUE SPECIFICITY: Expressed in neurons. Isoform PNS-tau is expressed in the peripheral nervous system while the others are expressed in the central nervous system.
DEVELOPMENTAL STAGE: Four-repeat (type II) TAU/MAPT is expressed in an adult-specific manner and is not found in fetal brain, whereas three-repeat (type I) TAU/MAPT is found in both adult and fetal brain.
DOMAIN: The tau/MAP repeat binds to tubulin. Type I isoforms contain 3 repeats while type II isoforms contain 4 repeats.
PTM: Phosphorylation at serine and threonine residues in S-P or T- P motifs by proline-directed protein kinases (PDPK1: CDK1, CDK5, GSK3, MAPK) (only 2-3 sites per protein in interphase, seven-fold increase in mitosis, and in the form associated with paired helical filaments (PHF-tau)), and at serine residues in K-X-G-S motifs by MAP/microtubule affinity-regulating kinase (MARK1 or MARK2), causing detachment from microtubules, and their disassembly. Phosphorylation decreases with age. Phosphorylation within tau/MAP's repeat domain or in flanking regions seems to reduce tAU/MAP's interaction with, respectively, microtubules or plasma membrane components. Phosphorylation on Ser-610, Ser-622, Ser-641 and Ser-673 in several isoforms during mitosis. Phosphorylation at Ser-548 by GSK3B reduces ability to bind and stabilize microtubules. Phosphorylation at Ser-579 by BRSK1 and BRSK2 in neurons affects ability to bind microtubules and plays a role in neuron polarization. Phosphorylated at Ser-554, Ser-579, Ser-602, Ser-606 and Ser-669 by PHK. Phosphorylation at Ser-214 by SGK1 mediates microtubule depolymerization and neurite formation in hippocampal neurons. There is a reciprocal down-regulation of phosphorylation and O-GlcNAcylation. Phosphorylation on Ser-717 completely abolishes the O-GlcNAcylation on this site, while phosphorylation on Ser-713 and Ser-721 reduces glycosylation by a factor of 2 and 4 respectively. Phosphorylation on Ser-721 is reduced by about 41.5% by GlcNAcylation on Ser-717.
PTM: Polyubiquitinated. Requires functional TRAF6 and may provoke SQSTM1-dependent degradation by the proteasome (By similarity). PHF-tau can be modified by three different forms of polyubiquitination. 'Lys-48'-linked polyubiquitination is the major form, 'Lys-6'-linked and 'Lys-11'-linked polyubiquitination also occur.
PTM: O-glycosylated. O-GlcNAcylation content is around 8.2%. There is reciprocal down-regulation of phosphorylation and O- GlcNAcylation. Phosphorylation on Ser-717 completely abolishes the O-GlcNAcylation on this site, while phosphorylation on Ser-713 and Ser-721 reduces O-GlcNAcylation by a factor of 2 and 4 respectively. O-GlcNAcylation on Ser-717 decreases the phosphorylation on Ser-721 by about 41.5%.
PTM: Glycation of PHF-tau, but not normal brain TAU/MAPT. Glycation is a non-enzymatic post-translational modification that involves a covalent linkage between a sugar and an amino group of a protein molecule forming ketoamine. Subsequent oxidation, fragmentation and/or cross-linking of ketoamine leads to the production of advanced glycation endproducts (AGES). Glycation may play a role in stabilizing PHF aggregation leading to tangle formation in AD.
DISEASE: Note=In Alzheimer disease, the neuronal cytoskeleton in the brain is progressively disrupted and replaced by tangles of paired helical filaments (PHF) and straight filaments, mainly composed of hyperphosphorylated forms of TAU (PHF-TAU or AD P- TAU). O-GlcNAcylation is greatly reduced in Alzheimer disease brain cerebral cortex leading to an increase in TAU/MAPT phosphorylations.
DISEASE: Defects in MAPT are a cause of frontotemporal dementia (FTD) [MIM:600274]; also called frontotemporal dementia (FTD), pallido-ponto-nigral degeneration (PPND) or historically termed Pick complex. This form of frontotemporal dementia is characterized by presenile dementia with behavioral changes, deterioration of cognitive capacities and loss of memory. In some cases, parkinsonian symptoms are prominent. Neuropathological changes include frontotemporal atrophy often associated with atrophy of the basal ganglia, substantia nigra, amygdala. In most cases, protein tau deposits are found in glial cells and/or neurons.
DISEASE: Defects in MAPT are a cause of Pick disease of the brain (PIDB) [MIM:172700]. It is a rare form of dementia pathologically defined by severe atrophy, neuronal loss and gliosis. It is characterized by the occurrence of tau-positive inclusions, swollen neurons (Pick cells) and argentophilic neuronal inclusions known as Pick bodies that disproportionally affect the frontal and temporal cortical regions. Clinical features include aphasia, apraxia, confusion, anomia, memory loss and personality deterioration.
DISEASE: Note=Defects in MAPT are a cause of corticobasal degeneration (CBD). It is marked by extrapyramidal signs and apraxia and can be associated with memory loss. Neuropathologic features may overlap Alzheimer disease, progressive supranuclear palsy, and Parkinson disease.
DISEASE: Defects in MAPT are a cause of progressive supranuclear palsy type 1 (PSNP1) [MIM:601104]; also abbreviated as PSP and also known as Steele-Richardson-Olszewski syndrome. PSNP1 is characterized by akinetic-rigid syndrome, supranuclear gaze palsy, pyramidal tract dysfunction, pseudobulbar signs and cognitive capacities deterioration. Neurofibrillary tangles and gliosis but no amyloid plaques are found in diseased brains. Most cases appear to be sporadic, with a significant association with a common haplotype including the MAPT gene and the flanking regions. Familial cases show an autosomal dominant pattern of transmission with incomplete penetrance; genetic analysis of a few cases showed the occurrence of tau mutations, including a deletion of Asn-613.
DISEASE: Defects in MAPT are a cause of Parkinson-dementia syndrome (PARDE) [MIM:260540]. A syndrome characterized by parkinsonism tremor, rigidity, dementia, ophthalmoparesis and pyramidal signs. Neurofibrillary degeneration occurs in the hippocampus, basal ganglia and brainstem nuclei.
SIMILARITY: Contains 4 Tau/MAP repeats.
WEB RESOURCE: Name=Alzheimer Research Forum; Note=Tau mutations; URL="http://www.alzforum.org/res/com/mut/tau/default.asp";
WEB RESOURCE: Name=Protein Spotlight; Note=Vita minima - Issue 68 of March 2006; URL="http://web.expasy.org/spotlight/back_issues/sptlt068.shtml";
WEB RESOURCE: Name=GeneReviews; URL="http://www.ncbi.nlm.nih.gov/sites/GeneTests/lab/gene/MAPT";
WEB RESOURCE: Name=Wikipedia; Note=Tau protein entry; URL="http://en.wikipedia.org/wiki/Tau_protein";

-  Genetic Association Studies of Complex Diseases and Disorders
  Genetic Association Database (archive): MAPT
CDC HuGE Published Literature: MAPT
Positive Disease Associations: , Alzheimer Disease|Alzheimer's Disease , Alzheimer's Disease , cognitive ability , dementia, frontotemporal , Familial atypical progressive supranuclear palsy , frontotemporal dementia and Pick-like 3R and 4R tauopathy , Hip , inherited dementia FTDP-17 , Neurodegenerative Diseases|Supranuclear Palsy, Progressive , Parkinson Disease , Parkinson's disease , primary progressive aphasia , progressive supranuclear palsy , Supranuclear Palsy, Progressive
Related Studies:

  1. John S K Kauwe , et al. Proceedings of the National Academy of Sciences of the United States of America 2008 105(23):8050-4, Variation in MAPT is associated with cerebrospinal fluid tau levels in the presence of amyloid-beta deposition., Proceedings of the National Academy of Sciences of the United States of America 2008 105(23):8050-4. [PubMed 18541914]
  2. Alzheimer Disease|Alzheimer's Disease
    Di Maria E et al. 2010, The H1 Haplotype of the Tau Gene (MAPT) is Associated with Mild Cognitive Impairment., Journal of Alzheimer's disease : JAD 19(3) : 909-14 2010. [PubMed 20157246]
    Case-control analysis showed that the common H1 haplotype of the tau protein gene (MAPT) is significantly overrepresented in patients with mild cognitive impairment. This finding was confirmed when the ε4 allele of the APOE gene was taken into account. The study firstly suggested that the risk of mild cognitive impairment is influenced by tau protein gene variations and that mild cognitive impairment shares a common genetic background with Alzheimer's disease.
  3. Alzheimer's Disease
    Bullido MJ et al. 2000, A polymorphism in the tau gene associated with risk for Alzheimer's disease., Neuroscience letters. 2000 Jan;278(2-Jan):49-52. [PubMed 10643798]
           more ... click here to view the complete list

-  MalaCards Disease Associations
  MalaCards Gene Search: MAPT
Diseases sorted by gene-association score: pick disease* (1270), supranuclear palsy, progressive* (1238), dementia, frontotemporal* (888), supranuclear palsy, progressive atypical* (550), parkinson disease, late-onset* (427), mapt-related disorders* (100), frontotemporal dementia with parkinsonism-17* (100), dementia (49), corticobasal degeneration (29), semantic dementia (27), alzheimer disease (25), classic progressive supranuclear palsy syndrome* (25), progressive supranuclear palsy-progressive non-fluent aphasia syndrome* (25), progressive supranuclear palsy-corticobasal syndrome* (25), progressive supranuclear palsy-pure akinesia with gait freezing syndrome* (25), agraphia (22), postencephalitic parkinson disease (22), aphasia (20), apraxia (18), normal pressure hydrocephalus (17), multiple system atrophy (15), vascular dementia (14), creutzfeldt-jakob disease (13), inclusion body myositis (13), posterior cortical atrophy (13), dementia, lewy body (12), progressive non-fluent aphasia* (11), amyotrophic lateral sclerosis-parkinsonism/dementia complex (11), frontotemporal lobar degeneration with ubiquitin-positive inclusions (11), behavioral variant of frontotemporal dementia* (10), motor neuron disease (10), parkinson disease 5 (10), synucleinopathy (9), tremor (9), ideomotor apraxia (9), leukoencephalopathy, diffuse hereditary, with spheroids (8), speech and communication disorders (8), wernicke encephalopathy (8), panencephalitis, subacute sclerosing (8), myxoid chondrosarcoma (7), nominal aphasia (7), basal ganglia disease (7), communicating hydrocephalus (7), learning disability (6), central nervous system disease (6), neuronal intranuclear inclusion disease (6), snca-related parkinson disease (6), aneurysmal bone cysts (6), posterior myocardial infarction (6), myositis (6), prion disease (6), akinetic mutism (6), movement disease (6), hydrocephalus (6), alzheimer disease mitochondrial (6), parkinson disease susceptibility (5), spinocerebellar ataxia 11 (5), mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (5), niemann-pick disease, type c1 (5), kluver-bucy syndrome (5), alzheimer disease-2 (5), breast abscess (4), amyotrophic lateral sclerosis 1 (4), binswanger's disease (4), streptococcal meningitis (4), byssinosis (3), nervous system disease (2), disease of mental health (1)
* = Manually curated disease association

-  Comparative Toxicogenomics Database (CTD)
  The following chemicals interact with this gene           more ... click here to view the complete list

+  Common Gene Haplotype Alleles
  Press "+" in the title bar above to open this section.

-  RNA-Seq Expression Data from GTEx (53 Tissues, 570 Donors)
  Highest median expression: 50.30 RPKM in Brain - Cerebellum
Total median expression: 458.70 RPKM



View in GTEx track of Genome Browser    View at GTEx portal     View GTEx Body Map

+  Microarray Expression Data
  Press "+" in the title bar above to open this section.

-  mRNA Secondary Structure of 3' and 5' UTRs
 
RegionFold EnergyBasesEnergy/Base
Display As
5' UTR -138.72322-0.431 Picture PostScript Text
3' UTR -1622.404162-0.390 Picture PostScript Text

The RNAfold program from the Vienna RNA Package is used to perform the secondary structure predictions and folding calculations. The estimated folding energy is in kcal/mol. The more negative the energy, the more secondary structure the RNA is likely to have.

-  Protein Domain and Structure Information
  InterPro Domains: Graphical view of domain structure
IPR001084 - Tau/MAP_tubulin-bd_rpt
IPR002955 - Tau_protein

Pfam Domains:
PF00418 - Tau and MAP protein, tubulin-binding repeat

Protein Data Bank (PDB) 3-D Structure
MuPIT help

1I8H
- NMR

3FQP
- X-ray

3OVL
- X-ray


ModBase Predicted Comparative 3D Structure on P10636
FrontTopSide
The pictures above may be empty if there is no ModBase structure for the protein. The ModBase structure frequently covers just a fragment of the protein. You may be asked to log onto ModBase the first time you click on the pictures. It is simplest after logging in to just click on the picture again to get to the specific info on that model.

-  Orthologous Genes in Other Species
  Orthologies between human, mouse, and rat are computed by taking the best BLASTP hit, and filtering out non-syntenic hits. For more distant species reciprocal-best BLASTP hits are used. Note that the absence of an ortholog in the table below may reflect incomplete annotations in the other species rather than a true absence of the orthologous gene.
MouseRatZebrafishD. melanogasterC. elegansS. cerevisiae
No orthologGenome BrowserNo orthologNo orthologNo orthologNo ortholog
 Gene Details    
 Gene Sorter    
 RGD    
 Protein Sequence    
 Alignment    

-  Gene Ontology (GO) Annotations with Structured Vocabulary
  Molecular Function:
GO:0003677 DNA binding
GO:0003680 AT DNA binding
GO:0003690 double-stranded DNA binding
GO:0003697 single-stranded DNA binding
GO:0003723 RNA binding
GO:0003779 actin binding
GO:0005515 protein binding
GO:0008017 microtubule binding
GO:0015631 tubulin binding
GO:0017124 SH3 domain binding
GO:0019899 enzyme binding
GO:0019901 protein kinase binding
GO:0030674 protein binding, bridging
GO:0034185 apolipoprotein binding
GO:0034452 dynactin binding
GO:0035091 phosphatidylinositol binding
GO:0042802 identical protein binding
GO:0042803 protein homodimerization activity
GO:0043565 sequence-specific DNA binding
GO:0048018 receptor agonist activity
GO:0051087 chaperone binding
GO:0051721 protein phosphatase 2A binding
GO:0051879 Hsp90 protein binding
GO:0071813 lipoprotein particle binding
GO:0099077 histone-dependent DNA binding
GO:0099609 microtubule lateral binding
GO:1902936 phosphatidylinositol bisphosphate binding

Biological Process:
GO:0000226 microtubule cytoskeleton organization
GO:0001774 microglial cell activation
GO:0006475 internal protein amino acid acetylation
GO:0006919 activation of cysteine-type endopeptidase activity involved in apoptotic process
GO:0007267 cell-cell signaling
GO:0007416 synapse assembly
GO:0007611 learning or memory
GO:0007613 memory
GO:0010288 response to lead ion
GO:0010469 regulation of receptor activity
GO:0010506 regulation of autophagy
GO:0010629 negative regulation of gene expression
GO:0010917 negative regulation of mitochondrial membrane potential
GO:0016072 rRNA metabolic process
GO:0019896 axonal transport of mitochondrion
GO:0021954 central nervous system neuron development
GO:0031110 regulation of microtubule polymerization or depolymerization
GO:0031113 regulation of microtubule polymerization
GO:0031116 positive regulation of microtubule polymerization
GO:0031122 cytoplasmic microtubule organization
GO:0031175 neuron projection development
GO:0032930 positive regulation of superoxide anion generation
GO:0033044 regulation of chromosome organization
GO:0033673 negative regulation of kinase activity
GO:0034063 stress granule assembly
GO:0034605 cellular response to heat
GO:0034614 cellular response to reactive oxygen species
GO:0045773 positive regulation of axon extension
GO:0046785 microtubule polymerization
GO:0048143 astrocyte activation
GO:0048167 regulation of synaptic plasticity
GO:0048312 intracellular distribution of mitochondria
GO:0048699 generation of neurons
GO:0050808 synapse organization
GO:0050848 regulation of calcium-mediated signaling
GO:0051259 protein oligomerization
GO:0051260 protein homooligomerization
GO:0061564 axon development
GO:0070507 regulation of microtubule cytoskeleton organization
GO:0072386 plus-end-directed organelle transport along microtubule
GO:0090140 regulation of mitochondrial fission
GO:0090258 negative regulation of mitochondrial fission
GO:0097435 supramolecular fiber organization
GO:0098930 axonal transport
GO:1900034 regulation of cellular response to heat
GO:1900452 regulation of long term synaptic depression
GO:1901216 positive regulation of neuron death
GO:1902474 positive regulation of protein localization to synapse
GO:1902988 neurofibrillary tangle assembly
GO:1903748 negative regulation of establishment of protein localization to mitochondrion
GO:1903829 positive regulation of cellular protein localization
GO:1904428 negative regulation of tubulin deacetylation
GO:1905689 positive regulation of diacylglycerol kinase activity
GO:1990000 amyloid fibril formation
GO:1990090 cellular response to nerve growth factor stimulus
GO:1990416 cellular response to brain-derived neurotrophic factor stimulus
GO:2001020 regulation of response to DNA damage stimulus

Cellular Component:
GO:0005576 extracellular region
GO:0005622 intracellular
GO:0005634 nucleus
GO:0005737 cytoplasm
GO:0005739 mitochondrion
GO:0005829 cytosol
GO:0005856 cytoskeleton
GO:0005874 microtubule
GO:0005875 microtubule associated complex
GO:0005886 plasma membrane
GO:0015630 microtubule cytoskeleton
GO:0016020 membrane
GO:0016607 nuclear speck
GO:0030424 axon
GO:0030425 dendrite
GO:0030426 growth cone
GO:0030673 axolemma
GO:0034399 nuclear periphery
GO:0036464 cytoplasmic ribonucleoprotein granule
GO:0036477 somatodendritic compartment
GO:0042995 cell projection
GO:0043025 neuronal cell body
GO:0043197 dendritic spine
GO:0044297 cell body
GO:0044304 main axon
GO:0045298 tubulin complex
GO:0097418 neurofibrillary tangle
GO:1904115 axon cytoplasm


-  Descriptions from all associated GenBank mRNAs
  JA482023 - Sequence 6 from Patent WO2011072091.
JA482024 - Sequence 7 from Patent WO2011072091.
JA482025 - Sequence 8 from Patent WO2011072091.
JA482026 - Sequence 9 from Patent WO2011072091.
JA482027 - Sequence 10 from Patent WO2011072091.
JA482028 - Sequence 11 from Patent WO2011072091.
JE980315 - Sequence 6 from Patent EP2862929.
JE980316 - Sequence 7 from Patent EP2862929.
JE980317 - Sequence 8 from Patent EP2862929.
JE980318 - Sequence 9 from Patent EP2862929.
JE980319 - Sequence 10 from Patent EP2862929.
JE980320 - Sequence 11 from Patent EP2862929.
AK095802 - Homo sapiens cDNA FLJ38483 fis, clone FEBRA2022972, highly similar to Homo sapiens microtubule-associated protein tau (MAPT), transcript variant 4, mRNA.
AK299658 - Homo sapiens cDNA FLJ57789 complete cds, highly similar to Homo sapiens microtubule-associated protein tau (MAPT), transcript variant 4, mRNA.
AK299704 - Homo sapiens cDNA FLJ60852 complete cds, highly similar to Homo sapiens microtubule-associated protein tau (MAPT), transcript variant 4, mRNA.
BC000558 - Homo sapiens microtubule-associated protein tau, mRNA (cDNA clone IMAGE:3162763), complete cds.
J03778 - Human microtubule-associated protein tau mRNA, complete cds.
BC099721 - Homo sapiens microtubule-associated protein tau, mRNA (cDNA clone IMAGE:40007443), complete cds.
BC101936 - Homo sapiens microtubule-associated protein tau, mRNA (cDNA clone IMAGE:40007441), complete cds.
BC098281 - Homo sapiens microtubule-associated protein tau, mRNA (cDNA clone IMAGE:40007442), complete cds.
BC114504 - Homo sapiens microtubule-associated protein tau, transcript variant 4, mRNA (cDNA clone IMAGE:40007444), complete cds.
BC114948 - Homo sapiens microtubule-associated protein tau, mRNA (cDNA clone IMAGE:40007445), complete cds.
X14474 - Human mRNA for microtubule-associated tau protein.
BT006772 - Homo sapiens microtubule-associated protein tau mRNA, complete cds.
KJ891579 - Synthetic construct Homo sapiens clone ccsbBroadEn_00973 MAPT gene, encodes complete protein.
KR711803 - Synthetic construct Homo sapiens clone CCSBHm_00031040 MAPT (MAPT) mRNA, encodes complete protein.
KR711804 - Synthetic construct Homo sapiens clone CCSBHm_00031060 MAPT (MAPT) mRNA, encodes complete protein.
AY730549 - Homo sapiens microtubule-associated tau protein mRNA, complete cds.
JD399206 - Sequence 380230 from Patent EP1572962.
JD141958 - Sequence 122982 from Patent EP1572962.
JD323523 - Sequence 304547 from Patent EP1572962.
JD564072 - Sequence 545096 from Patent EP1572962.
AK226139 - Homo sapiens mRNA for Splice isoform Tau-C of P10636 variant, clone: pg00222.
AK024390 - Homo sapiens cDNA FLJ14328 fis, clone PLACE4000252.
FJ429137 - Homo sapiens high molecular weight microtubule-associated protein tau mRNA, exon 4A-L and partial cds, alternatively spliced.
AY526356 - Homo sapiens microtubule-associated protein tau mRNA, partial cds.
M25298 - Homo sapiens tau protein (a microtubule-associated phosphoprotein) extra inserted repeat mRNA, partial cds.
MA000381 - JP 2018002694-A/1: Prophylactic or therapeutic agent for cancer.
JD282600 - Sequence 263624 from Patent EP1572962.
JD540373 - Sequence 521397 from Patent EP1572962.
AB073354 - Homo sapiens primary neuroblastoma cDNA, clone:Nbla03755, full insert sequence.
JD133045 - Sequence 114069 from Patent EP1572962.
JD543537 - Sequence 524561 from Patent EP1572962.
JD052859 - Sequence 33883 from Patent EP1572962.
JD112610 - Sequence 93634 from Patent EP1572962.
JD089851 - Sequence 70875 from Patent EP1572962.
JD280515 - Sequence 261539 from Patent EP1572962.
JD339636 - Sequence 320660 from Patent EP1572962.
JD500613 - Sequence 481637 from Patent EP1572962.
JD283863 - Sequence 264887 from Patent EP1572962.
JD496220 - Sequence 477244 from Patent EP1572962.
JD266925 - Sequence 247949 from Patent EP1572962.
JD485377 - Sequence 466401 from Patent EP1572962.
JD476029 - Sequence 457053 from Patent EP1572962.
JD109049 - Sequence 90073 from Patent EP1572962.
JD480252 - Sequence 461276 from Patent EP1572962.
JD186443 - Sequence 167467 from Patent EP1572962.
JD476515 - Sequence 457539 from Patent EP1572962.
JD406491 - Sequence 387515 from Patent EP1572962.
JD193475 - Sequence 174499 from Patent EP1572962.
BC071830 - Homo sapiens cDNA clone IMAGE:6277209, partial cds.
BC094805 - Homo sapiens cDNA clone IMAGE:5015789.
JD262986 - Sequence 244010 from Patent EP1572962.
JD402055 - Sequence 383079 from Patent EP1572962.
JD376886 - Sequence 357910 from Patent EP1572962.
JD206388 - Sequence 187412 from Patent EP1572962.
BC061892 - Homo sapiens cDNA clone IMAGE:3457926, partial cds.
JD054808 - Sequence 35832 from Patent EP1572962.
JD143780 - Sequence 124804 from Patent EP1572962.
LF782138 - JP 2016523980-A/7: MicroRNAs that Silence Tau Expression.
AK055986 - Homo sapiens cDNA FLJ31424 fis, clone NT2NE2000392.
JD554584 - Sequence 535608 from Patent EP1572962.
JD345145 - Sequence 326169 from Patent EP1572962.
JD105193 - Sequence 86217 from Patent EP1572962.
JD470589 - Sequence 451613 from Patent EP1572962.
JD491832 - Sequence 472856 from Patent EP1572962.
JD420740 - Sequence 401764 from Patent EP1572962.
JD548633 - Sequence 529657 from Patent EP1572962.
JD492807 - Sequence 473831 from Patent EP1572962.
AF456477 - Homo sapiens G protein beta1/gamma2 subunit-interacting factor 1, partial sequence.
BC032572 - Homo sapiens cDNA clone IMAGE:5244499.
JD114888 - Sequence 95912 from Patent EP1572962.
JD476868 - Sequence 457892 from Patent EP1572962.
BC040444 - Homo sapiens microtubule-associated protein tau, mRNA (cDNA clone IMAGE:5770508).
JD075951 - Sequence 56975 from Patent EP1572962.
JD391264 - Sequence 372288 from Patent EP1572962.
JD163713 - Sequence 144737 from Patent EP1572962.
JD326539 - Sequence 307563 from Patent EP1572962.
JD349101 - Sequence 330125 from Patent EP1572962.
JD404589 - Sequence 385613 from Patent EP1572962.
JD252260 - Sequence 233284 from Patent EP1572962.
JD062506 - Sequence 43530 from Patent EP1572962.
JD133159 - Sequence 114183 from Patent EP1572962.
JD133160 - Sequence 114184 from Patent EP1572962.
JD472973 - Sequence 453997 from Patent EP1572962.
JD121481 - Sequence 102505 from Patent EP1572962.
JD362563 - Sequence 343587 from Patent EP1572962.
JD303690 - Sequence 284714 from Patent EP1572962.
JD053623 - Sequence 34647 from Patent EP1572962.
JD206971 - Sequence 187995 from Patent EP1572962.
JD203114 - Sequence 184138 from Patent EP1572962.
JD561498 - Sequence 542522 from Patent EP1572962.
JD479257 - Sequence 460281 from Patent EP1572962.
LF782137 - JP 2016523980-A/6: MicroRNAs that Silence Tau Expression.
JD124585 - Sequence 105609 from Patent EP1572962.
JD474106 - Sequence 455130 from Patent EP1572962.
JD325143 - Sequence 306167 from Patent EP1572962.
JD253961 - Sequence 234985 from Patent EP1572962.
JD253542 - Sequence 234566 from Patent EP1572962.
JD115342 - Sequence 96366 from Patent EP1572962.
JD358916 - Sequence 339940 from Patent EP1572962.
JD318324 - Sequence 299348 from Patent EP1572962.
JD470208 - Sequence 451232 from Patent EP1572962.
JD234462 - Sequence 215486 from Patent EP1572962.
JD271063 - Sequence 252087 from Patent EP1572962.
JD527883 - Sequence 508907 from Patent EP1572962.
JD097904 - Sequence 78928 from Patent EP1572962.
JD257206 - Sequence 238230 from Patent EP1572962.
JD109898 - Sequence 90922 from Patent EP1572962.
JD502041 - Sequence 483065 from Patent EP1572962.
JD528658 - Sequence 509682 from Patent EP1572962.
JD220854 - Sequence 201878 from Patent EP1572962.
JD467805 - Sequence 448829 from Patent EP1572962.
JD429491 - Sequence 410515 from Patent EP1572962.
LF782139 - JP 2016523980-A/8: MicroRNAs that Silence Tau Expression.
JD316208 - Sequence 297232 from Patent EP1572962.

-  Biochemical and Signaling Pathways
  KEGG - Kyoto Encyclopedia of Genes and Genomes
hsa04010 - MAPK signaling pathway
hsa05010 - Alzheimer's disease

Reactome (by CSHL, EBI, and GO)

Protein P10636 (Reactome details) participates in the following event(s):

R-HSA-201629 Caspase-mediated cleavage of Tau
R-HSA-264870 Caspase-mediated cleavage of cytoskeletal proteins
R-HSA-111465 Apoptotic cleavage of cellular proteins
R-HSA-75153 Apoptotic execution phase
R-HSA-109581 Apoptosis
R-HSA-5357801 Programmed Cell Death

-  Other Names for This Gene
  Alternate Gene Symbols: MAPTL, MTBT1, NM_016835, NP_058519, P10636, P18518, Q14799, Q15549, Q15550, Q15551, Q1RMF6, Q53YB1, Q5CZI7, Q5XWF0, Q6QT54, Q9UDJ3, Q9UMH0, Q9UQ96, TAU, TAU_HUMAN
UCSC ID: uc002ijr.4
RefSeq Accession: NM_016835
Protein: P10636 (aka TAU_HUMAN)
CCDS: CCDS11501.1, CCDS45715.1

-  Gene Model Information
 
category: coding nonsense-mediated-decay: no RNA accession: NM_016835.4
exon count: 14CDS single in 3' UTR: no RNA size: 6762
ORF size: 2277CDS single in intron: no Alignment % ID: 100.00
txCdsPredict score: 4547.00frame shift in genome: no % Coverage: 99.99
has start codon: yes stop codon in genome: no # of Alignments: 2
has end codon: yes retained intron: no # AT/AC introns 0
selenocysteine: no end bleed into intron: 0# strange splices: 0
Click here for a detailed description of the fields of the table above.

-  Methods, Credits, and Use Restrictions
  Click here for details on how this gene model was made and data restrictions if any.